- Home
- NATH vs PROK Comparison
NATH vs PROK Comparison
Compare NATH & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NATH | PROK |
|---|---|---|
| Founded | 1916 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.8M | 359.1M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NATH | PROK |
|---|---|---|
| Price | $100.73 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 14.0K | ★ 904.1K |
| Earning Date | 06-09-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.85 | N/A |
| Revenue | ★ $104,201,000.00 | $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.82 | ★ N/A |
| Revenue Growth | 7.81 | ★ 1075.00 |
| 52 Week Low | $88.67 | $0.54 |
| 52 Week High | $117.49 | $7.13 |
Technical Indicators
Market Signals| Indicator | NATH | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 44.27 | 47.87 |
| Support Level | $100.26 | $1.73 |
| Resistance Level | $101.76 | $2.59 |
| Average True Range (ATR) | 0.73 | 0.11 |
| MACD | -0.14 | 0.01 |
| Stochastic Oscillator | 3.60 | 41.27 |
Price Performance
Historical ComparisonAbout NATH Nathan's Famous Inc.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.